Omega-3 API maker KD Pharma snaps up U.K. manufacturing site for undisclosed price

Pills and vitamins
The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. (Steven Depolo/CC BY 2.0)

KD Pharma, a Swiss API maker of omega-3 products, has snapped up a manufacturing site in Seal Sands, U.K., for an undisclosed price.

The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. The Seal Sands facility was previously used to make omega-3 products.

KD Pharma, which employs about 400 people globally, has seven sites situated in the U.K. and U.S. The company makes omega-3 fatty acid products that are used in finished products like soft gel capsules and bottled liquid forms of pharmaceutical products.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

“The acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” Oscar Groet, KD Pharma’s chief executive, said in a statement. “The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids.”

The Seal Sands plant is expected to be up and running for KD Pharma by the end of the year. The company’s other sites include Bexbach, Germany, Brattvagm, Norway and Miami.

Read more on

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

As flights from China contract and prices double, the logistics of getting products out of China is a major challenge. 

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.